SBE13 hydrochloride

• CAT Number: I000284
• CAS Number: 1052532-15-6
• Molecular Formula: C₂₄H₂₇ClN₂O₄.HCl
• Molecular Weight: 479.40
• Purity: ≥95%
• Synonyms: N-(4-((6-chloropyridin-3-yl)methoxy)-3-methoxybenzyl)-2-(3,4-dimethoxyphenyl)ethanamine hydrochloride
• Target: PLK
• Solubility: DMSO: ≥ 42 mg/mL
• Storage: Store at -20°C
• IC50: 0.2 nM [1]
• IUPAC Name: N-[[4-[(6-chloropyridin-3-yl)methoxy]-3-methoxyphenyl]methyl]-2-(3,4-dimethoxyphenyl)ethanamine;hydrochloride
• InChI: InChI=1S/C24H27ClN2O4.ClH/c1-28-20-7-4-17(12-22(20)29-2)10-11-26-14-18-5-8-21(23(13-18)30-3)31-16-19-6-9-24(25)27-15-19;/h4-9,12-13,15,26H,10-11,14,16H2,1-3H3;1H
• InChIKey: QBGSVDJLQQXEGG-UHFFFAOYSA-N
• SMILES: COC1=C(C=C(C=C1)CCNCC2=CC(=C(C=C2)OCC3=CN=C(C=C3)Cl)OC)OC.Cl

SBE13 Hydrochloride（Cat No.:I000284）is a potent and selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone crucial for the stability and function of several oncogenic proteins. By inhibiting Hsp90, SBE13 destabilizes and degrades its client proteins, leading to the disruption of key signaling pathways involved in cancer cell growth and survival. This compound is commonly used in cancer research to explore Hsp90 inhibition as a therapeutic strategy. SBE13 Hydrochloride’s ability to target multiple cancer-driving proteins makes it valuable in the study and development of anticancer therapies.

Reference

[1]. Keppner S, et al. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9.
[2]. Lange L, et al. Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status. Oncotarget. 2014 Apr 30;5(8):2263-75.
[3]. Keppner S, et al. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73.